Sage, Biogen post fresh phase 3 depression data as FDA filing nears completion

Sage Therapeutics and Biogen have shared a closer look at phase 3 data on zuranolone in postpartum depression (PPD), presenting secondary endpoint results from SKYLARK while racing to wrap up a filing for FDA approval.